Comparison tool
MOTS-c vs Oxytocin side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | MOTS-c | Oxytocin |
|---|---|---|
| Category | Hormonal | Hormonal |
| Also known as | Mitochondrial ORF of the 12S rRNA type-c | Pitocin, Syntocinon, The Love Hormone |
| FDA approved | No | Yes |
| Clinical status | Preclinical; source notes early human studies beginning and FDA Category 2 status pending formal reclassification review.
| FDA approved for labor and postpartum use; other uses remain under research
|
| What to expect | Metabolic health, exercise performance, insulin sensitivity | Social bonding, anxiety, trust, emotional wellbeing |
| How it works | MOTS-c is presented as a mitochondrial peptide with a proposed metabolic signaling role. The source links its activity to AMPK activation after effects on folate-AICAR-one-carbon metabolism, with downstream research interest in fatty-acid oxidation, glucose handling, and mitochondrial biogenesis. It also reports that MOTS-c may enter the nucleus during metabolic stress and influence stress-response genes, a mechanism that remains under investigation. | Oxytocin acts through the oxytocin receptor, a G-protein-coupled receptor described in the source as present in the uterus, breast tissue, and multiple brain areas including the amygdala. In peripheral tissues, signaling is linked to calcium-mediated uterine contraction and milk ejection. Central effects are described as modulation of fear, reward, and social-attention circuitry, but intranasal research is difficult to interpret because the amount reaching the brain is uncertain and may involve indirect pathways. |
| Typical dosing | 5-10 mg weekly · 1-3x weekly | 10-24 IU intranasal as needed · As needed · Intranasal |
| Research dosing | 5-10 mg daily · Variable by protocol · Subcutaneous injection | 10-40 IU IV for labor · Single dose or short-term use · IV (obstetric); intranasal (research) |
| Typical duration | Variable by protocol | Single dose or short-term use |
| Administration | Subcutaneous injection | IV in obstetric labeling; intranasal in research contexts |
| Timing | Morning or pre-workout Empty stomach | As needed in studied social or bonding contexts With or without food |
| Evidence level | Preclinical | FDA Approved |
| Possible side effects |
+5 more
|
+4 more
|
| Research summary | The supplied source reports strong preclinical interest in MOTS-c, especially in mouse models where it is associated with improved insulin sensitivity, resistance to diet-induced obesity, and longer treadmill running in older animals. Human evidence in the source is more limited and described as observational: exercise was reported to increase MOTS-c in skeletal muscle and circulation. The source also states that, as of 2026, completed published randomized human trials have not shown supplemental MOTS-c to produce weight loss, metabolic improvement, or longevity effects in people. It is also noted as relevant to anti-doping monitoring, reinforcing its experimental and performance-related research context. | The source treats injectable obstetric oxytocin as established, while describing intranasal behavioral research as contested. For social reward, a 2023 systematic review covering 19 randomized, double-blind, placebo-controlled studies and about 984 participants reported a clearer signal in brain-activity outcomes than in behavior or self-report. In autism research, the source cites a 2021 Scientific Reports randomized trial that did not find a substantial empathy-related neural activation change, and it notes that repeated-dose studies have ranged from modest social-behavior findings to no clear effect. Context and sex-specific differences are presented as important reasons the findings remain difficult to generalize. Short-term intranasal trial safety was described as reassuring, but the source does not establish a reliable clinical benefit for these investigational uses. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.